Genocea to Present at Upcoming Conferences
CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in October.
Scientific conferences:
| Event: | AACR: Tumor Immunology and Immunotherapy – Details |
| Topic: | GEN-011: A neoantigen-targeted peripheral blood-derived T cell therapy that has broad neoantigen specificity and high T cell purity while avoiding pro-tumor cells |
| Format: | Poster presentation |
| Date: | Tuesday-Wednesday, October 5-6th |
| Time: | Available throughout the conference |
| Event: | Meeting on the Mesa – Details |
| Topic: | Next-generation neoantigen-targeted solid tumor T cell therapy |
| Format: | Presentation |
| Date: | Tuesday-Thursday, October 12-14th |
| Time: | Available throughout the conference |
| Event: | CMO Summit – Details |
| Topic: | Communicating and Pivoting After a Failed Clinical Trial |
| Format: | Panel |
| Date: | Friday, October 15th |
| Time: | 1:00 p.m. ET |
| Event: | TIL Therapies Digital Summit – Details |
| Topic: | Identification of InhibigensTM May be the Key to Successful T cell Therapies for Solid Tumors |
| Format: | Presentation |
| Date: | Tuesday, October 19th |
| Time: | 11:00 a.m. ET |
| Event: | Neoantigen-Based Therapies Summit – Details |
| Topic 1: | Prioritizing Diversity, Equity, and Inclusion in the Neoantigen Field |
| Roundtable discussion | |
| 12:40 p.m. ET | |
| Topic 2: | Responses to Inhibitory Tumor Antigens, InhibigensTM, Suppresses Anti-Tumor Immunity & promote Tumor Growth |
| Presentation | |
| Wednesday, October 27th | |
| 12:30 p.m. ET | |
| Topic 3: | Unleashing the Titans: The GEN-011 Neoantigen-Targeted Peripheral T cell Therapy for Solid Tumors |
| Presentation | |
| Wednesday, October 27th | |
| 5:30 p.m. ET |
About Genocea Biosciences, Inc.
Genocea’s mission is to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer. Our proprietary ATLAS™ platform can comprehensively profile each patient’s T cell responses to potential targets, or antigens, on that patient’s tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, Inhibigens™, that drive pro-tumor immune responses. We are conducting a Phase 1/2a clinical trial for GEN-011, our investigational adoptive T cell therapy comprising neoantigen-targeted peripheral cells. We continue to monitor patients in our phase 1/2a clinical trial for GEN-009, our investigational neoantigen vaccine. In addition to our two clinical programs, we are conducting research in several areas where we believe ATLAS could be a key tool in optimizing antigen selection for therapies across a number of diseases. To learn more, please visit https://www.genocea.com.
